Artificial Pancreas Device Systems (APDS) Market Trends

Artificial Pancreas Device Systems Market Trends

Rising demand for automated glycemic control systems such as APDS, technological advancements in CGM sensors, and increase in investment towards research and development by key players is driving the market progress. Technological improvements have transformed CGM sensors into smaller, more accurate, and less invasive devices, greatly enhancing patient comfort and overall usability. This heightened accuracy ensures that APDS can make precise insulin dosing adjustments, resulting in improved glycemic control and a reduced risk of hypoglycemia and hyperglycemia. As these technological advancements expand the appeal of APDS to a broader user base and gain increased clinical endorsement.
 

Traditional diabetes management methods involve multiple daily injections or manual adjustments of insulin doses, that can be burdensome and challenging for patients to maintain consistently. Thus, the demand for automated systems such as APDS is increasing among diabetic patients. Moreover, as demand increases, medical device companies are focusing on developing more advanced solutions, which can be another factor in the high adoption of APDS. For instance, the Medtronic MiniMed 780G artificial pancreas system has received approval from the Food and Drug Administration (FDA) for use in individuals aged 7 and above. This system offers automatic adjustments and real-time corrections to blood sugar levels at 5-minute intervals, including correction doses, as part of its meal detection technology.